Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma Not Eligible for High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation (BPV).

NCT02237261 is registered in ClinicalTrials.gov with University Hospital Heidelberg as lead sponsor.

NCT NCT02237261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02237261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma Not Eligible for High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation (BPV).
Lead sponsor
University Hospital Heidelberg
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2014
Completion date
October 31, 2018
Enrollment
46 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma